The Effect of Peri-percutaneous Coronary Intervention Oxygenation on

Status Completed

Clinical Trial Summary

Elective percutaneous coronary intervention (PCI) is often associated with myocardial necrosis evidenced by peri-procedural troponin release. This is a surrogate for subsequent cardiovascular events. There is no study on the effect of peri-PCI oxygenation in in myocardial protection and cardiopulmonary fitness outcome. Patients with higher baseline cardiopulmonary fitness will have lower mortality.

This study is to assess the utility of oxygen to reduce ischaemia in patients with significant stable coronary artery disease scheduled for elective PCI. The secondary objective is to evaluate further effect of peri- PCI oxygenation on cardiovascular fitness and autonomic response.

Clinical Trial Description

OBJECTIVE: This study is to assess the utility of oxygen to reduce ischaemia in patients with significant stable coronary artery disease scheduled for elective PCI. The secondary objective is to evaluate further effect of peri- PCI oxygenation on cardiovascular fitness and autonomic response.

STUDY DESIGN: Randomized double blinded prospective pilot study SAMPLE SIZE: 30 patients scheduled for elective for PCI randomized to 2 groups, oxygen group ( 15L/min) and air group METHOD: Patient whom fulfil inclusion criteria were recruited and randomized to 2 groups via computer allocation system. The assigned inhaled gas will be delivered via high-flow mask at 15L/min for a minimum of 30 minutes immediately prior to and continued throughout the PCI procedure. Patients were blinded throughout the procedure but the practising cardiologist and staff nurses were not blinded. Routine care continued post PCI. Blood sampling for Troponin I was taken at 6 hours and 24 hours following stent implantation. Patients were discharged one day after the procedure as per current routine practice.

Patients were given routine follow up with the cardiac rehabilitation clinic in 4 weeks time post discharge. EST was arranged 6 weeks post procedure PRIMARY OUTCOME MEASURE: Troponin I at 6 and 24 hours SECONDARY OUTCOME MEASURE: METs, Heart Rate Recovery, Chronotropic Index ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03256175
Study type	Interventional
Source	University of Malaya
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2015
Completion date	June 30, 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Recruiting	`NCT05846893` - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease	N/A
Completed	`NCT04153006` - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Active, not recruiting	`NCT04555174` - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting	`NCT04582877` - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Recruiting	`NCT03265535` - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting	`NCT04522583` - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Terminated	`NCT02407626` - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery	N/A
Completed	`NCT02554006` - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Active, not recruiting	`NCT02189499` - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent	Phase 2
Completed	`NCT02264717` - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease	N/A
Completed	`NCT02197065` - Pilot Study of Atorvastatin for Orthopedic Surgery Patients	Phase 2
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Completed	`NCT01679886` - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women	N/A
Terminated	`NCT01892917` - BIOFLOW-III Hungary Satellite Registry	N/A
Completed	`NCT01655043` - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI	Phase 2
Completed	`NCT01434043` - Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Peri-percutaneous Coronary Intervention Oxygenation on Myocardial Protection & Cardiovascular Fitness

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms